Related Patent Info

Provided are methods for changing the pluripotency state of a vertebrate cell to a more naive state, the methods comprising: culturing a pluripotent vertebrate cell in the presence of a serine/threonine-protein kinase B-Raf (BRAF) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor 1 (VEGFR1) inhibitor, or a fibroblast growth factor receptor 1 (FGFR1) inhibitor.

Provided are heterocyclic compounds that inhibit mitochondrial respiration and lead to the growth and maintained pluripotency of pluripotent stem cells even under ambient oxygen conditions. Exemplified compounds are substituted 5-aminotetrazoles, which are reversible mitochondrial inhibitors.

Provided are in vitro assay systems using pluripotent cells for simulating and modeling early steps in cell specification, differentiation and morphogenesis, enabling drug target identification and drug screening, in which the cells are dissociated to single cells and synchronized to initiate processes of cell specification and morphogenesis.

Provided is a cell culture substrate comprising a polymer formed of a cyclosiloxane compound and a manufacturing method therefor, and a method for preparing an aggregate of spheroid-like cells or iPS cells using the cell culture substrate.

The invention relates to a medium composition for generating iPS cells, containing an Ecklonia cava extract.

Disclosed are improved methods and compositions related to highly efficient generation of lymphoid-cell derived iPS cells using non-integrating episomal plasmid vectors, enabling provision of an enormous and renewable bioresource for regenerative medicine.

Disclosed is a kinetically controlled process for creating iPS cells, specifically relating to the use of synthetic mRNA cocktails encoding fusions between reprogramming factors with transactivation domains, e.g. an N-terminal MyoD transactivation domain. Also disclosed are methods for feeder-free and xeno-free derivation of human iPS cells using synthetic messenger RNAs.

The present invention relates to a method for generating iPS cells from mesenchymal stem cells by using a medium composition containing a phlorotannin isolated from a brown algae such as Ecklonia cava, Dictyopteris prolifera, Dictyota coriacea, Sargassum horneri, and Ishige okamurai.

The present invention relates to a method for somatic cell reprogramming to pluripotency by contacting somatic cells with the 30S or 50S bacterial ribosomal fraction.

The application of induced pluripotent stem cells (iPSCs) to generate adoptive cell therapy products and usage of iPSCs for screening potential toxicity of immune receptors are described herein. In some aspects, iPSCs and cells differentiated therefrom are provide which do not express a HLA gene (e.g., HLA-A).

This disclosure provides a chemically modified induced pluripotent stem (iPS) cells characterized by DNA hypomethylation and methods for generating the cells. The cells are useful in method for or regenerating cardiac muscle tissue or to promote the replacement of cardiac scar tissue in a patient in need thereof and to treat cardiac disease.

Disclosed herein are compositions, systems, and methods for modulating proliferation, differentiation and pluripotency of cells.

The purpose of the present invention is to provide a medium for propagation of stem cells with good performance that reduces the use of albumin while maintaining medium performance stability. The present invention provides a medium for iPS cell propagation characterized by including a water-soluble polymer such as polyvinyl alcohol with albumin.

The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material.

A method is disclosed for the generation of pluripotent cells from non-pluripotent cells.

There is provided a method of inducing pluripotency in a hematopoietic cell.

The invention provides compositions and methods for manufacturing pluripotent cells. In particular, the invention provides improved culture platforms for manufacturing pluripotent cells with ground state pluripotency.

Provided are a method for inducing the transdifferentiation of somatic cells into neural stem cells and application for same.

The present invention relates to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell and a use thereof and, more specifically, to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell.

Provided is a diseased humanized model animal that makes it possible to perform in vivo examination of human tissue and human cells that are in a diseased state.

A method of screenin therapeutic agents for Noonan syndrome using embryoid bodies and neural rosettes obtained from patient-derived iPS cells via chemical differentiation.

A method for obtaining iPS cell-derived differentiated cells that do not form cancer cells within a mammal, comprising guided differentiation of iPS cells generated using non-integrating viral vectors.

A method of nuclear reprogramming of a mammalian somatic cell, comprising contacting the cell with (a) an innate immune response activator and (b) a cocktail of mRNAs encoding reprogramming factors.

A method for inducing reprograming of a cell of a first type which is not a non-hepatocyte (non-hepatocyte cell), into a cell with functional hepatic drug metabolizing and transporting capabilities, is disclosed. The non-hepatocyte is induced to express or overexpress hepatic fate conversion and maturation factors, cultured in somatic cell culture medium, hepatocyte cell culture medium and hepatocyte maturation medium for a sufficient period of time to convert the non-hepatocyte cell into a cell with hepatocyte-like properties. The iHeps induced according to the methods disclosed herein are functional induced hepatocytes (iHeps) in that they express I and II drug-metabolizing enzymes and phase III drug transporters and show superior drug metabolizing activity compared to iHeps obtained by prior art methods. The iHeps thus provide a cell resource for pharmaceutical applications.

The present invention relates to an induced pluripotent stem cell (iPSC) model of Noonan syndrome, a preparation method therefor, and uses to be used in the study of the pathogenesis of Noonan syndrome and in a therapeutic agent screening method. Particularly, generation and differentiation of induced pluripotent stem cells (iPSCs) derived from Noonan syndrome, embryoid bodies (EB), and neural rosettes were induced from fibroblasts from a patient with Noonan syndrome and it was ascertained that iPSCs derived from Noonan syndrome exhibit the morphology and differentiation potency of normal iPSCs. In addition, as a result of inducing natural differentiation and chemical differentiation in order to differentiate iPSCs derived from Noonan syndrome into embryoid bodies and neural rosettes, embryoid bodies and neural rosettes induced via chemical differentiation exhibit cell morphology similar to that of normal cells and significantly express ectoderm, neural rosette, and neuron marker genes. Thus, the cellular model can be useful in analytical research for the pathogenesis of Noonan syndrome and in analytical research for the therapeutic agent screening method.

This document provides methods and materials related to making and using differentiated induced pluripotent stem cells. For example, methods and materials for making differentiated induced pluripotent stem cells (e.g., insulin-producing cells) that do not form cancer cells within a mammal (e.g., a human), cells that underwent guided differentiation from induced pluripotent stem cells, compositions containing cells that underwent guided differentiation from induced pluripotent stem cells, and methods for using cells that underwent guided differentiation from induced pluripotent stem cells (e.g., methods for using such cells to treat diabetes or to repair cardiovascular tissue) are provided.

The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.

Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs ("m-iPSCs"). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.

The invention provides a composition and a method for inducing pluripotency in non-pluripotent eukaryotic cells. The composition comprises chemical inducers of pluripotency (CIPs) including glycogen synthase kinase (GSK) inhibitors, TGFp receptor inhibitors, cyclic AMP agonists, S-adenosylhomocysteine hydrolase (SAH) inhibitors, and optionally an agent that promotes histone acetylation. The method comprises contacting a cell with the CIPs for a sufficient period of time to reprogram the cell into a pluripotent stem cell.

The present invention relates to: a method for preparing an osteoblast from a somatic cell by introducing a bone-related gene or an expression product thereof and a reprogramming-related gene or an expression product thereof to a somatic cell of a mammal, or introducing a reprogramming-related gene or an expression product thereof independently to a somatic cell of a mammal, the method for preparing an osteoblast in which the bone-related gene is at least one gene selected from the group consisting of Runx2 (R), Osterix (O), and Dlx5 (D), and the reprogramming-related gene is at least one gene selected from the group consisting of the Oct family, c-Myc (M), L-Myc (L), the Klf family, Lin-28, and Sox2; and an osteoblast prepared by the abovementioned method.